QPS Holding, LLC

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a small bioanalysis shop to a full service CRO with over 1100 employees in the US, Europe, India and Asia Pacific. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development.


Numerous acquisitions have strengthened QPS’ preclinical, early and late phase drug development capabilities worldwide.


Through continual enhancements in capacities and resources, QPS stands tall in its commitment to deliver superior quality, skilled performance and trusted service to its valued customers.


For more information, visit​ or send an e-mail to​.

Related resources



QPS | 18-Apr-2016 | Product Brochure

In recent years, society as well as pharmaceutical and biotech industries have gained interest in rare diseases. As a consequence increasing research efforts...

Seeking Drug Approval via the 505(b)(2) NDA Option

Seeking Drug Approval via the 505(b)(2) NDA Option

QPS | 07-May-2015 | Technical / White Paper

Today, many pharmaceutical companies are choosing the 505(b)(2) New Drug Approval (NDA) regulatory pathway. The 505(b)(2) NDA route relies on investigations...

Transdermal Delivery Systems

Transdermal Delivery Systems

QPS | 01-May-2014 | Technical / White Paper

Whereas dermatologic topical formulations (foams, creams, lotions, ointments, gels, etc.) target skin diseases, topical transdermal delivery systems (TDDS)...